Atea Pharmaceuticals Inc - Asset Resilience Ratio
Atea Pharmaceuticals Inc (AVIR) has an Asset Resilience Ratio of 61.53% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AVIR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Atea Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Atea Pharmaceuticals Inc (AVIR) total assets.
Liquid Assets Composition Over Time
This chart breaks down Atea Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Atea Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $142.92 Million | 61.53% |
| Total Liquid Assets | $142.92 Million | 61.53% |
Asset Resilience Insights
- Very High Liquidity: Atea Pharmaceuticals Inc maintains exceptional liquid asset reserves at 61.53% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Atea Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Atea Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Atea Pharmaceuticals Inc (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Atea Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 65.39% | $206.12 Million | $315.22 Million | -18.55pp |
| 2024-12-31 | 83.94% | $390.02 Million | $464.67 Million | +10.94pp |
| 2023-12-31 | 72.99% | $434.28 Million | $594.97 Million | +4.26pp |
| 2022-12-31 | 68.73% | $458.25 Million | $666.71 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $772.89 Million | -- |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company … Read more